impact of the keynote-045 study comparing pembrolizumab and chemotherapy in bladder cancer
Published 7 years ago • 128 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
0:58
significance of keynote-045 trial of pembrolizumab vs chemotherapy in urothelial carcinoma
-
1:19
dr. bellmunt shares keynote-045 data for pembrolizumab versus chemotherapy in bladder cancer
-
1:54
two-year follow-up results from keynote-045 study in urothelial carcinoma
-
1:09
keynote-045 – pembrolizumab as second-line treatment in urothelial carcinoma
-
1:18
dr. plimack on keynote-045 trial for pembrolizumab in urothelial carcinoma
-
1:53
discussing recent advances and clinical trials in bladder cancer
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
0:57
dr. petrylak on the keynote-045 trial for urothelial carcinoma
-
4:49
hrqol of pembrolizumab vs. chemotherapy for previously treated...
-
2:58
dr. bellmunt discusses follow-up data for pembrolizumab vs chemotherapy in bladder cancer
-
1:06
immunotherapy impacts in bladder cancer
-
1:08
incorporating immunotherapy in the frontline treatment of patients with bladder cancer
-
3:51
is pembrolizumab alone sufficient to treat bladder cancer?
-
10:35
management of bcg unresponsive cystectomy ineligible bladder cancer patients pembrolizumab
-
2:15
results of a first-line study of pembrolizumab in advanced urothelial cancer
-
1:34
dr. garcia on fda approval of pembrolizumab in bladder cancer
-
1:29:54
examining the state of the science on new therapies in bladder cancer
-
2:57
highlights in bladder canceres: keynote-045 keynote-052 dr. fabio schutz
-
1:38
keynote 361: pembrolizumab compared to gemcarbo - bladder cancer video library